[The role of voriconazole in the treatment of emerging mycoses]

Rev Iberoam Micol. 2007 Sep 30;24(3):228-32. doi: 10.1016/s1130-1406(07)70048-7.
[Article in Spanish]

Abstract

Voriconazole is a broad-spectrum antifungal drug belonging to triazoles class. Recently, it has been recommended for the treatment of invasive candidiasis in non neutropenic patients. In addition, this drug has showed clinical efficacy in the treatment of fungal infections caused by Candida species other than Candida albicans, and also in several other infections caused by less common fungi, such as Aspergillus terreus, Fusarium and Scedosporium.

Publication types

  • Review

MeSH terms

  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / drug therapy
  • Aspergillosis / microbiology
  • Candidiasis / drug therapy
  • Candidiasis / microbiology
  • Communicable Diseases, Emerging / drug therapy*
  • Communicable Diseases, Emerging / microbiology
  • Fusarium / drug effects
  • Humans
  • Mycoses / drug therapy*
  • Opportunistic Infections / drug therapy
  • Opportunistic Infections / microbiology
  • Paecilomyces / drug effects
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Scedosporium / drug effects
  • Triazoles / pharmacology
  • Triazoles / therapeutic use*
  • Voriconazole

Substances

  • Antifungal Agents
  • Pyrimidines
  • Triazoles
  • Voriconazole